Absolute B cell counts in blood predict long-term response in follicular lymphoma patients treated with rituximab without chemotherapy.
Adult
Aged
Aged, 80 and over
Antineoplastic Agents
/ therapeutic use
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
B-Lymphocytes
Clinical Trials, Phase II as Topic
/ statistics & numerical data
Clinical Trials, Phase III as Topic
/ statistics & numerical data
Datasets as Topic
Female
Follow-Up Studies
Humans
Immunosuppressive Agents
/ therapeutic use
Interferon alpha-2
/ administration & dosage
Kaplan-Meier Estimate
Lymphocyte Count
Lymphocyte Subsets
Lymphoma, Follicular
/ blood
Male
Middle Aged
Monocytes
Multicenter Studies as Topic
/ statistics & numerical data
Prognosis
Randomized Controlled Trials as Topic
/ statistics & numerical data
Rituximab
/ administration & dosage
Young Adult
B cell
Follicular lymphoma
Lymphocyte
Monocyte
Rituximab
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
04
06
2020
accepted:
27
07
2020
pubmed:
19
8
2020
medline:
2
10
2020
entrez:
19
8
2020
Statut:
ppublish
Résumé
Rituximab monotherapy is widely used for follicular lymphoma. However, there are no established predictors for response or response duration. We analyzed the long-term prognostic relevance of pre-treatment absolute blood counts of lymphocytes with subsets and monocytes in 265 follicular lymphoma patients, uniformly treated with rituximab without chemotherapy, in two Nordic Lymphoma Group trials. There were 265 previously untreated, stage II-IV follicular lymphoma patients with a median follow-up of over 10 years. Absolute B cell counts ≥ median (0.09 × 10
Identifiants
pubmed: 32808106
doi: 10.1007/s00277-020-04208-x
pii: 10.1007/s00277-020-04208-x
pmc: PMC7481163
doi:
Substances chimiques
Antineoplastic Agents
0
Immunosuppressive Agents
0
Interferon alpha-2
0
Rituximab
4F4X42SYQ6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2357-2366Références
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon
Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, Au WY, Bellei M, Brice P, Caballero D, Coiffier B, Conde-Garcia E, Doyen C, Federico M, Fisher RI, Garcia-Conde JF, Guglielmi C, Hageenbeek A, Haioun C, LeBlanc M, Lister AT, Lopez-Guillermo A, McLaughlin P, Milpied N, Morel P, Mounier N, Proctor SJ, Rohatiner A, Smith P, Soubeyran P, Tilly H, Vitolo U, Zinzani PL, Zucca E, Montserrat E (2004) Follicular Lymphoma International Prognostic Index. Blood 104(5):1258–1265. https://doi.org/10.1182/blood-2003-12-4434
doi: 10.1182/blood-2003-12-4434
pubmed: 15126323
Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W (2006) The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 108(5):1504–1508
doi: 10.1182/blood-2006-01-013367
Sugimoto T, Watanabe T (2016) Follicular lymphoma: the role of the tumor microenvironment in prognosis. J Clin Exp Hematop 56(1):1–19. https://doi.org/10.3960/jslrt.56.1
doi: 10.3960/jslrt.56.1
pubmed: 27334853
pmcid: 6247780
Wahlin BE, Sundstrom C, Holte H, Hagberg H, Erlanson M, Nilsson-Ehle H, Linden O, Nordstrom M, Ostenstad B, Geisler CH, Brown Pde N, Lehtinen T, Maisenholder M, Tierens AM, Sander B, Christensson B, Kimby E (2011) T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab. Clin Cancer Res 17(12):4136–4144. https://doi.org/10.1158/1078-0432.CCR-11-0264
doi: 10.1158/1078-0432.CCR-11-0264
pubmed: 21518780
Cartron G, Watier H, Golay J, Solal-Celigny P (2004) From the bench to the bedside: ways to improve rituximab efficacy. Blood 104(9):2635–2642
doi: 10.1182/blood-2004-03-1110
Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Colgan JP, Nowakowski GS, Ansell SM, Witzig TE, Markovic SN, Porrata L (2012) The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma. Leuk Lymphoma 53(4):575–580. https://doi.org/10.3109/10428194.2011.637211
doi: 10.3109/10428194.2011.637211
pubmed: 22098403
Tadmor T, Bari A, Sacchi S, Marcheselli L, Liardo EV, Avivi I, Benyamini N, Attias D, Pozzi S, Cox MC, Baldini L, Brugiatelli M, Federico M, Polliack A (2014) Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era. Haematologica 99(1):125–130. https://doi.org/10.3324/haematol.2013.088161
doi: 10.3324/haematol.2013.088161
pubmed: 23935023
pmcid: 4007925
von Hohenstaufen KA, Conconi A, de Campos CP, Franceschetti S, Bertoni F, Margiotta Casaluci G, Stathis A, Ghielmini M, Stussi G, Cavalli F, Gaidano G, Zucca E (2013) Prognostic impact of monocyte count at presentation in mantle cell lymphoma. Br J Haematol 162(4):465–473. https://doi.org/10.1111/bjh.12409
doi: 10.1111/bjh.12409
Yang YQ, Liang JH, Wu JZ, Wang L, Qu XY, Cao L, Zhao XL, Huang DP, Fan L, Li JY, Xu W (2016) Elevated absolute monocyte count predicts unfavorable outcomes in patients with angioimmunoblastic T-cell lymphoma. Leuk Res 42:88–92. https://doi.org/10.1016/j.leukres.2015.12.010
doi: 10.1016/j.leukres.2015.12.010
pubmed: 26764222
Huang JJ, Li YJ, Xia Y, Wang Y, Wei WX, Zhu YJ, Lin TY, Huang HQ, Jiang WQ, Li ZM (2013) Prognostic significance of peripheral monocyte count in patients with extranodal natural killer/T-cell lymphoma. BMC Cancer 13:222. https://doi.org/10.1186/1471-2407-13-222
doi: 10.1186/1471-2407-13-222
pubmed: 23638998
pmcid: 3653743
Siddiqui M, Ristow K, Markovic SN, Witzig TE, Habermann TM, Colgan JP, Inwards DJ, White WL, Ansell SM, Micallef IN, Johnston PB, Call TG, Porrata LF (2006) Absolute lymphocyte count predicts overall survival in follicular lymphomas. Br J Haematol 134(6):596–601
doi: 10.1111/j.1365-2141.2006.06232.x
Behl D, Ristow K, Markovic SN, Witzig TE, Habermann TM, Colgan JP, Inwards DJ, White WL, Ansell SM, Micallef IN, Johnston PB, Porrata LF (2007) Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas. Br J Haematol 137(5):409–415. https://doi.org/10.1111/j.1365-2141.2007.06596.x
doi: 10.1111/j.1365-2141.2007.06596.x
pubmed: 17433025
Ghielmini M, Rufibach K, Salles G, Leoncini-Franscini L, Leger-Falandry C, Cogliatti S, Fey M, Martinelli G, Stahel R, Lohri A, Ketterer N, Wernli M, Cerny T, Schmitz SF (2005) Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 16(10):1675–1682
doi: 10.1093/annonc/mdi320
Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 339(21):1506–1514. https://doi.org/10.1056/nejm199811193392104
doi: 10.1056/nejm199811193392104
pubmed: 9819449
Kim DH, Baek JH, Chae YS, Kim YK, Kim HJ, Park YH, Song HS, Chung JS, Hyun MS, Sohn SK (2007) Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma. Leukemia 21(10):2227–2230. https://doi.org/10.1038/sj.leu.2404780
doi: 10.1038/sj.leu.2404780
pubmed: 17554383
Castillo JJ, Morales D, Quinones P, Cotrina E, Desposorio C, Beltran B (2010) Lymphopenia as a prognostic factor in patients with peripheral T-cell lymphoma, unspecified. Leuk Lymphoma 51(10):1822–1828. https://doi.org/10.3109/10428194.2010.508189
doi: 10.3109/10428194.2010.508189
pubmed: 20849388
Mitrovic Z, Perry AM, Suzumiya J, Armitage JO, Au WY, Coiffier B, Holte H, Jaffe ES, Monserrat E, Rajan SK, Savage KJ, Tobinai K, Vose JM, Weisenburger DD (2012) The prognostic significance of lymphopenia in peripheral T-cell and natural killer/T-cell lymphomas: a study of 826 cases from the International Peripheral T-cell Lymphoma Project. Am J Hematol 87(8):790–794. https://doi.org/10.1002/ajh.23205
doi: 10.1002/ajh.23205
pubmed: 22488678
pmcid: 6329305
Wahlin BE, Sundstrom C, Sander B, Christensson B, Jeppsson-Ahlberg A, Hjalmarsson E, Holte H, Ostenstad B, Brown PD, Smeland EB, Kimby E (2014) Higher World Health Organization grades of follicular lymphoma correlate with better outcome in two Nordic Lymphoma Group trials of rituximab without chemotherapy. Leuk Lymphoma 55(2):288–295. https://doi.org/10.3109/10428194.2013.802778
doi: 10.3109/10428194.2013.802778
pubmed: 23662992
Kimby E, Jurlander J, Geisler C, Hagberg H, Holte H, Lehtinen T, Ostenstad B, Hansen M, Osterborg A, Linden O, Sundstrom C (2008) Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group. Leuk Lymphoma 49(1):102–112. https://doi.org/10.1080/10428190701704647
doi: 10.1080/10428190701704647
pubmed: 18203019
Kimby E, Ostenstad B, Brown P, Hagberg H, Erlanson M, Holte H, Linden O, Johansson AS, Ahlgren T, Wader K, Wahlin BE, Delabie J, Sundstrom C (2015) Two courses of four weekly infusions of rituximab with or without interferon-alpha2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas. Leuk Lymphoma 1–10. https://doi.org/10.3109/10428194.2015.1014363
Lockmer S, Ostenstad B, Hagberg H, Holte H, Johansson AS, Wahlin BE, Wader KF, Steen CB, Meyer P, Maisenholder M, Smedby KE, Brown P, Kimby E (2018) Chemotherapy-free initial treatment of advanced indolent lymphoma has durable effect with low toxicity: results from two Nordic Lymphoma Group trials with more than 10 years of follow-up. J Clin Oncol JCO1800262. https://doi.org/10.1200/JCO.18.00262
Mims MP (2018) Lymphocytosis, lymphocytopenia, hypergammaglobulinemia, and hypogammaglobulinemia. In: EJB RH Jr, Silberstein LE, Heslop H, Weitz J, Anastasi J (eds) Hematology, basic principles and practice, 7th edn. Churchill Livingstone/Elsevier, Philadelphia, pp 682–690
Watanabe R, Tomita N, Kishimoto K, Koyama S, Ogusa E, Ishii Y, Miyashita K, Matsuura S, Fujisawa S, Hattori Y, Takasaki H, Fujita A, Ohshima R, Kuwabara H, Hashimoto C, Fujimaki K, Sakai R, Ishigatsubo Y (2013) Absolute monocyte count in follicular lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Leuk Res 37(10):1208–1212. https://doi.org/10.1016/j.leukres.2013.07.015
doi: 10.1016/j.leukres.2013.07.015
pubmed: 23927994
Marcheselli L, Bari A, Anastasia A, Botto B, Puccini B, Dondi A, Carella AM, Alvarez I, Chiarenza A, Arcari A, Salvi F, Federico M (2015) Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi. Br J Haematol 169(4):544–551. https://doi.org/10.1111/bjh.13332
doi: 10.1111/bjh.13332
pubmed: 25817296
Beltran BE, Quiñones P, Morales D, Alva JC, Miranda RN, Lu G, Shah BD, Sotomayor EM, Castillo JJ (2013) Follicular lymphoma with leukemic phase at diagnosis: a series of seven cases and review of the literature. Leuk Res 37(9):1116–1119. https://doi.org/10.1016/j.leukres.2013.05.016
doi: 10.1016/j.leukres.2013.05.016
pubmed: 23790442
pmcid: 4038155
Maeshima AM, Taniguchi H, Tanioka K, Kitahara H, Miyamoto K, Fukuhara S, Munakata W, Suzuki T, Maruyama D, Kobayashi Y, Tobinai K, Kushima R (2015) Clinicopathological characteristics of follicular lymphoma with peripheral blood involvement. Leuk Lymphoma 56(7):2000–2004. https://doi.org/10.3109/10428194.2014.963578
doi: 10.3109/10428194.2014.963578
pubmed: 25315078
Sarkozy C, Baseggio L, Feugier P, Callet-Bauchu E, Karlin L, Seymour JF, Lebras L, Michallet AS, Offner F, Dumas O, Traverse-Glehen A, Ffrench M, Lopez-Guillermo A, Berger F, Coiffier B, Felman P, Salles G (2014) Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis. Br J Haematol 164(5):659–667. https://doi.org/10.1111/bjh.12675
doi: 10.1111/bjh.12675
pubmed: 24274024
Kodaira M, Takeuchi K, Nara E, Nakano K, Ueda K, Yamada S, Mishima Y, Yokoyama M, Terui Y, Hatake K (2009) Leukemic presentation is predictive indicator for relapse for patients with follicular lymphoma treated with rituximab containing initial therapy. Paper presented at the ASH Annual Meeting Abstracts, Dec 05–08
Sarkozy C, Seymour JF, Ferme C, Caballero D, Ghesquieres H, Leppa S, Delarue R, Pedersen LM, Mounier C, Gomes Da Silva M, Chassagne-Clement C, Maerevoet M, Salles G (2014) Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma. Blood 123(17):2740–2742. https://doi.org/10.1182/blood-2014-02-553693
doi: 10.1182/blood-2014-02-553693
pubmed: 24764560
Berinstein NL, Grillo-Lopez AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M, Green D, Rosenberg J, McLaughlin P, Shen D (1998) Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol 9(9):995–1001
doi: 10.1023/A:1008416911099
Jager U, Fridrik M, Zeitlinger M, Heintel D, Hopfinger G, Burgstaller S, Mannhalter C, Oberaigner W, Porpaczy E, Skrabs C, Einberger C, Drach J, Raderer M, Gaiger A, Putman M, Greil R, Arbeitsgemeinschaft Medikamentose Tumortherapie I (2012) Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica 97(9):1431–1438. https://doi.org/10.3324/haematol.2011.059246
doi: 10.3324/haematol.2011.059246
pubmed: 22511498
pmcid: 3436246
Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI (2013) A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab. Clin Cancer Res 19(23):6624–6632. https://doi.org/10.1158/1078-0432.ccr-13-1120
doi: 10.1158/1078-0432.ccr-13-1120
pubmed: 24130072
Bachy E, Maurer MJ, Habermann TM, Gelas-Dore B, Maucort-Boulch D, Estell JA, Van den Neste E, Bouabdallah R, Gyan E, Feldman AL, Bargay J, Delmer A, Slager SL, Gomes da Silva M, Fitoussi O, Belada D, Maisonneuve H, Intragumtornchai T, Ansell SM, Lamy T, Dartigues P, Link BK, Seymour JF, Cerhan JR, Salles G (2018) A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood 132(1):49–58. https://doi.org/10.1182/blood-2017-11-816405
doi: 10.1182/blood-2017-11-816405
pubmed: 29666118
pmcid: 6034646